215 related articles for article (PubMed ID: 35294533)
21. Genetic characteristics and response to systemic therapies of acral lentiginous melanoma at a tertiary care center-a retrospective review.
Jamerson T; Rebecca VW; Aguh C
J Natl Med Assoc; 2022 Feb; 114(1):7-11. PubMed ID: 34509302
[TBL] [Abstract][Full Text] [Related]
22. Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma.
Takai E; Omata W; Totoki Y; Nakamura H; Shiba S; Takahashi A; Namikawa K; Mori T; Yamazaki N; Shibata T; Yachida S
Cancer Sci; 2021 Nov; 112(11):4748-4757. PubMed ID: 34477284
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of CCNE1 copy number gain in acral melanoma patients.
Wu X; Yan J; Yu J; Cheng Z; Guo Q; Kong Y; Guo J
Melanoma Res; 2021 Aug; 31(4):352-357. PubMed ID: 33965974
[TBL] [Abstract][Full Text] [Related]
24. Analysis of KIT expression and gene mutation in human acral melanoma: with a comparison between primary tumors and corresponding metastases/recurrences.
Dai B; Cai X; Kong YY; Yang F; Shen XX; Wang LW; Kong JC
Hum Pathol; 2013 Aug; 44(8):1472-8. PubMed ID: 23528861
[TBL] [Abstract][Full Text] [Related]
25. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
[TBL] [Abstract][Full Text] [Related]
26. Meta-Analysis and Systematic Review of the Genomics of Mucosal Melanoma.
Broit N; Johansson PA; Rodgers CB; Walpole ST; Newell F; Hayward NK; Pritchard AL
Mol Cancer Res; 2021 Jun; 19(6):991-1004. PubMed ID: 33707307
[TBL] [Abstract][Full Text] [Related]
27. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
28. [Somatic Mutations Associated with Metastasis in Acral Melanoma].
Abramov IS; Emelyanova MA; Ryabaya OO; Krasnov GS; Zasedatelev AS; Nasedkina TV
Mol Biol (Mosk); 2019; 53(4):648-653. PubMed ID: 31397438
[TBL] [Abstract][Full Text] [Related]
29.
Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L
Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667
[No Abstract] [Full Text] [Related]
30. c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis.
Steeb T; Wessely A; Petzold A; Kohl C; Erdmann M; Berking C; Heppt MV
Eur J Cancer; 2021 Nov; 157():348-357. PubMed ID: 34562816
[TBL] [Abstract][Full Text] [Related]
31. Clinical features, molecular pathology, and immune microenvironmental characteristics of acral melanoma.
Gui J; Guo Z; Wu D
J Transl Med; 2022 Aug; 20(1):367. PubMed ID: 35974375
[TBL] [Abstract][Full Text] [Related]
32. Acral melanoma: correlating the clinical presentation to the mutational status.
Ravaioli GM; Dika E; Lambertini M; Chessa MA; Fanti PA; Patrizi A
G Ital Dermatol Venereol; 2019 Oct; 154(5):567-572. PubMed ID: 29512974
[TBL] [Abstract][Full Text] [Related]
33. Clinical and genetic analysis of melanomas arising in acral sites.
Zaremba A; Murali R; Jansen P; Möller I; Sucker A; Paschen A; Zimmer L; Livingstone E; Brinker TJ; Hadaschik E; Franklin C; Roesch A; Ugurel S; Schadendorf D; Griewank KG; Cosgarea I
Eur J Cancer; 2019 Sep; 119():66-76. PubMed ID: 31419753
[TBL] [Abstract][Full Text] [Related]
34. Patterns of genomic evolution in advanced melanoma.
Birkeland E; Zhang S; Poduval D; Geisler J; Nakken S; Vodak D; Meza-Zepeda LA; Hovig E; Myklebost O; Knappskog S; Lønning PE
Nat Commun; 2018 Jul; 9(1):2665. PubMed ID: 29991680
[TBL] [Abstract][Full Text] [Related]
35. Acral melanoma foot lesions. Part 1: epidemiology, aetiology, and molecular pathology.
Desai A; Ugorji R; Khachemoune A
Clin Exp Dermatol; 2017 Dec; 42(8):845-848. PubMed ID: 28940724
[TBL] [Abstract][Full Text] [Related]
36. Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
Gao HW; Tsai WC; Perng CL; Wang WM; Chiang CP
Eur J Dermatol; 2018 Aug; 28(4):509-518. PubMed ID: 30325319
[TBL] [Abstract][Full Text] [Related]
37. A Mutational Survey of Acral Nevi.
Smalley KSM; Teer JK; Chen YA; Wu JY; Yao J; Koomen JM; Chen WS; Rodriguez-Waitkus P; Karreth FA; Messina JL
JAMA Dermatol; 2021 Jul; 157(7):831-835. PubMed ID: 33978681
[TBL] [Abstract][Full Text] [Related]
38. Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis.
Hendricks WPD; Zismann V; Sivaprakasam K; Legendre C; Poorman K; Tembe W; Perdigones N; Kiefer J; Liang W; DeLuca V; Stark M; Ruhe A; Froman R; Duesbery NS; Washington M; Aldrich J; Neff MW; Huentelman MJ; Hayward N; Brown K; Thamm D; Post G; Khanna C; Davis B; Breen M; Sekulic A; Trent JM
PLoS Genet; 2018 Sep; 14(9):e1007589. PubMed ID: 30188888
[TBL] [Abstract][Full Text] [Related]
39. Integrated genomic analyses of acral and mucosal melanomas nominate novel driver genes.
Wang M; Banik I; Shain AH; Yeh I; Bastian BC
Genome Med; 2022 Jun; 14(1):65. PubMed ID: 35706047
[TBL] [Abstract][Full Text] [Related]
40. Distinct genetic profiles of extracranial and intracranial acral melanoma metastases.
Sharma G; Lian CG; Lin WM; Amin-Mansour A; Jané-Valbuena J; Garraway L; Bao W; Yoon CH; Ibrahim N
J Cutan Pathol; 2016 Oct; 43(10):884-91. PubMed ID: 27251777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
